Russell Investments Group Ltd. Sells 70,371 Shares of Sutro Biopharma, Inc. (NASDAQ:STRO)

Russell Investments Group Ltd. decreased its holdings in shares of Sutro Biopharma, Inc. (NASDAQ:STROFree Report) by 64.8% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 38,224 shares of the company’s stock after selling 70,371 shares during the quarter. Russell Investments Group Ltd. owned 0.06% of Sutro Biopharma worth $164,000 at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of STRO. Adage Capital Partners GP L.L.C. grew its stake in Sutro Biopharma by 1,275.7% in the 3rd quarter. Adage Capital Partners GP L.L.C. now owns 3,105,132 shares of the company’s stock worth $10,775,000 after buying an additional 2,879,412 shares in the last quarter. Acadian Asset Management LLC lifted its stake in Sutro Biopharma by 18.2% in the third quarter. Acadian Asset Management LLC now owns 773,867 shares of the company’s stock worth $2,684,000 after purchasing an additional 119,399 shares during the last quarter. Vontobel Holding Ltd. lifted its stake in shares of Sutro Biopharma by 42.5% in the 4th quarter. Vontobel Holding Ltd. now owns 641,684 shares of the company’s stock valued at $2,753,000 after acquiring an additional 191,345 shares during the last quarter. Exchange Traded Concepts LLC boosted its holdings in Sutro Biopharma by 34.0% during the 4th quarter. Exchange Traded Concepts LLC now owns 35,856 shares of the company’s stock valued at $154,000 after acquiring an additional 9,092 shares during the period. Finally, SG Americas Securities LLC grew its position in Sutro Biopharma by 25.6% during the 4th quarter. SG Americas Securities LLC now owns 40,779 shares of the company’s stock worth $175,000 after acquiring an additional 8,314 shares during the last quarter. 96.99% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on STRO shares. Wedbush reissued an “outperform” rating and set a $8.00 price objective on shares of Sutro Biopharma in a research note on Tuesday, May 14th. JMP Securities reissued a “market outperform” rating and set a $17.00 price target on shares of Sutro Biopharma in a research report on Wednesday, April 3rd. HC Wainwright restated a “buy” rating and issued a $12.00 price objective on shares of Sutro Biopharma in a research report on Tuesday, May 14th. Truist Financial dropped their target price on shares of Sutro Biopharma from $25.00 to $18.00 and set a “buy” rating for the company in a report on Wednesday, April 3rd. Finally, Piper Sandler reissued an “overweight” rating and issued a $11.00 target price (down from $12.00) on shares of Sutro Biopharma in a research note on Wednesday, April 3rd. Eight analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $12.50.

Check Out Our Latest Stock Report on Sutro Biopharma

Sutro Biopharma Price Performance

STRO stock opened at $4.08 on Friday. The firm has a 50-day moving average of $4.15 and a 200 day moving average of $4.00. The company has a market cap of $333.70 million, a P/E ratio of -2.17 and a beta of 1.09. Sutro Biopharma, Inc. has a 1 year low of $2.01 and a 1 year high of $6.13.

Sutro Biopharma (NASDAQ:STROGet Free Report) last released its earnings results on Monday, March 25th. The company reported $0.42 EPS for the quarter, beating analysts’ consensus estimates of ($0.82) by $1.24. The company had revenue of $113.72 million during the quarter, compared to analysts’ expectations of $12.16 million. Sutro Biopharma had a negative return on equity of 94.18% and a negative net margin of 74.61%. On average, equities research analysts expect that Sutro Biopharma, Inc. will post -3.19 earnings per share for the current fiscal year.

Sutro Biopharma Company Profile

(Free Report)

Sutro Biopharma, Inc operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer.

Read More

Want to see what other hedge funds are holding STRO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sutro Biopharma, Inc. (NASDAQ:STROFree Report).

Institutional Ownership by Quarter for Sutro Biopharma (NASDAQ:STRO)

Receive News & Ratings for Sutro Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sutro Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.